Literature DB >> 26976331

Homeostasis of the astrocytic glutamate transporter GLT-1 is altered in mouse models of Lafora disease.

Carmen Muñoz-Ballester1, Arnaud Berthier1, Rosa Viana1, Pascual Sanz2.   

Abstract

Lafora disease (LD, OMIM 254780) is a fatal rare disorder characterized by epilepsy and neurodegeneration. Although in recent years a lot of information has been gained on the molecular basis of the neurodegeneration that accompanies LD, the molecular basis of epilepsy is poorly understood. Here, we present evidence indicating that the homeostasis of glutamate transporter GLT-1 (EAAT2) is compromised in mouse models of LD. Our results indicate that primary astrocytes from LD mice have reduced capacity of glutamate transport, probably because they present a reduction in the levels of the glutamate transporter at the plasma membrane. On the other hand, the overexpression in cellular models of laforin and malin, the two proteins related to LD, results in an accumulation of GLT-1 (EAAT2) at the plasma membrane and in a severe reduction of the ubiquitination of the transporter. All these results suggest that the laforin/malin complex slows down the endocytic recycling of the GLT-1 (EAAT2) transporter. Since, defects in the function of this transporter lead to excitotoxicity and epilepsy, we suggest that the epilepsy that accompanies LD could be due, at least in part, to deficiencies in the function of the GLT-1 (EAAT2) transporter.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  EAAT2; Endocytosis; Epilepsy; GLT-1; Glutamate transport; Lafora disease; Protein recycling; Ubiquitination

Mesh:

Substances:

Year:  2016        PMID: 26976331      PMCID: PMC5472677          DOI: 10.1016/j.bbadis.2016.03.008

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  40 in total

Review 1.  Lafora disease: epidemiology, pathophysiology and management.

Authors:  Thomas S Monaghan; Norman Delanty
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

2.  Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease.

Authors:  Jordi Duran; Agnès Gruart; Mar García-Rocha; José M Delgado-García; Joan J Guinovart
Journal:  Hum Mol Genet       Date:  2014-01-22       Impact factor: 6.150

Review 3.  Toward a new role for plasma membrane sodium-dependent glutamate transporters of astrocytes: maintenance of antioxidant defenses beyond extracellular glutamate clearance.

Authors:  Laurence Had-Aissouni
Journal:  Amino Acids       Date:  2011-03-12       Impact factor: 3.520

Review 4.  Laforin, a protein with many faces: glucan phosphatase, adapter protein, et alii.

Authors:  Matthew S Gentry; Carlos Romá-Mateo; Pascual Sanz
Journal:  FEBS J       Date:  2012-03-16       Impact factor: 5.542

5.  Sumoylation of the astroglial glutamate transporter EAAT2 governs its intracellular compartmentalization.

Authors:  E Foran; L Rosenblum; A Bogush; P Pasinelli; D Trotti
Journal:  Glia       Date:  2014-04-21       Impact factor: 7.452

6.  Protein kinase C (PKC)-promoted endocytosis of glutamate transporter GLT-1 requires ubiquitin ligase Nedd4-2-dependent ubiquitination but not phosphorylation.

Authors:  Noemí García-Tardón; Inmaculada M González-González; Jaime Martínez-Villarreal; Enrique Fernández-Sánchez; Cecilio Giménez; Francisco Zafra
Journal:  J Biol Chem       Date:  2012-04-13       Impact factor: 5.157

Review 7.  Regulated exocytosis in astrocytic signal integration.

Authors:  Vladimir Parpura; Brandi J Baker; Matjaz Jeras; Robert Zorec
Journal:  Neurochem Int       Date:  2010-02-13       Impact factor: 3.921

8.  Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease.

Authors:  E Masliah; M Alford; R DeTeresa; M Mallory; L Hansen
Journal:  Ann Neurol       Date:  1996-11       Impact factor: 10.422

9.  Regulation of glycogen synthesis by the laforin-malin complex is modulated by the AMP-activated protein kinase pathway.

Authors:  Maria Carmen Solaz-Fuster; José Vicente Gimeno-Alcañiz; Susana Ros; Maria Elena Fernandez-Sanchez; Belen Garcia-Fojeda; Olga Criado Garcia; David Vilchez; Jorge Dominguez; Mar Garcia-Rocha; Maribel Sanchez-Piris; Carmen Aguado; Erwin Knecht; Jose Serratosa; Joan Josep Guinovart; Pascual Sanz; Santiago Rodriguez de Córdoba
Journal:  Hum Mol Genet       Date:  2007-11-20       Impact factor: 6.150

10.  Loss of GABAergic cortical neurons underlies the neuropathology of Lafora disease.

Authors:  Saida Ortolano; Irene Vieitez; Roberto Carlos Agis-Balboa; Carlos Spuch
Journal:  Mol Brain       Date:  2014-01-28       Impact factor: 4.041

View more
  10 in total

1.  Astrocytes: new players in progressive myoclonus epilepsy of Lafora type.

Authors:  Carla Rubio-Villena; Rosa Viana; Jose Bonet; Maria Adelaida Garcia-Gimeno; Marta Casado; Miguel Heredia; Pascual Sanz
Journal:  Hum Mol Genet       Date:  2018-04-01       Impact factor: 6.150

2.  Modulators of Neuroinflammation Have a Beneficial Effect in a Lafora Disease Mouse Model.

Authors:  Belén Mollá; Miguel Heredia; Pascual Sanz
Journal:  Mol Neurobiol       Date:  2021-01-14       Impact factor: 5.590

Review 3.  [Lafora disease: a review of the literature].

Authors:  L Desdentado; R Espert; P Sanz; J Tirapu-Ustarroz
Journal:  Rev Neurol       Date:  2019-01-16       Impact factor: 0.870

Review 4.  The role of astrocytic glutamate transporters GLT-1 and GLAST in neurological disorders: Potential targets for neurotherapeutics.

Authors:  Edward Pajarillo; Asha Rizor; Jayden Lee; Michael Aschner; Eunsook Lee
Journal:  Neuropharmacology       Date:  2019-03-06       Impact factor: 5.250

Review 5.  The 5th International Lafora Epilepsy Workshop: Basic science elucidating therapeutic options and preparing for therapies in the clinic.

Authors:  Matthew S Gentry; Zaid Afawi; Dustin D Armstrong; Antonio Delgado-Escueta; Y Paul Goldberg; Tamar R Grossman; Joan J Guinovart; Frank Harris; Thomas D Hurley; Roberto Michelucci; Berge A Minassian; Pascual Sanz; Carolyn A Worby; Jose M Serratosa
Journal:  Epilepsy Behav       Date:  2020-01-10       Impact factor: 2.937

6.  Efficacy and tolerability of perampanel in ten patients with Lafora disease.

Authors:  Danielle Goldsmith; Berge A Minassian
Journal:  Epilepsy Behav       Date:  2016-07-25       Impact factor: 2.937

Review 7.  Brain Glycogen Structure and Its Associated Proteins: Past, Present and Future.

Authors:  M Kathryn Brewer; Matthew S Gentry
Journal:  Adv Neurobiol       Date:  2019

Review 8.  Lafora Disease: A Ubiquitination-Related Pathology.

Authors:  Maria Adelaida García-Gimeno; Erwin Knecht; Pascual Sanz
Journal:  Cells       Date:  2018-07-26       Impact factor: 6.600

9.  Endocytosis of the glutamate transporter 1 is regulated by laforin and malin: Implications in Lafora disease.

Authors:  Eva Perez-Jimenez; Rosa Viana; Carmen Muñoz-Ballester; Carlos Vendrell-Tornero; Raquel Moll-Diaz; Maria Adelaida Garcia-Gimeno; Pascual Sanz
Journal:  Glia       Date:  2020-12-23       Impact factor: 7.452

Review 10.  Lafora disease: Current biology and therapeutic approaches.

Authors:  S Mitra; E Gumusgoz; B A Minassian
Journal:  Rev Neurol (Paris)       Date:  2021-07-21       Impact factor: 4.313

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.